Disease activity and treatment response in early rheumatoid arthritis: an exploratory metabolomic profiling in the NORD-STAR cohort.

Journal: Arthritis research & therapy
Published Date:

Abstract

BACKGROUND: The variability in treatment response in people with rheumatoid arthritis (RA) warrants the prediction of patients at high risk of treatment failure. Identification of biomarkers linked to clinical remission in RA is currently a challenge. Metabolomics may help to identify such biomarkers as it allows for a comprehensive exploration of disease-related variations that extends beyond the genome and proteome. This hypothesis-free exploratory metabolomics study aimed to profile serum metabolic alterations in early RA to understand the metabolic changes associated with disease activity and therapeutic response.

Authors

  • Tahzeeb Fatima
    Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden. tahzeeb.fatima@gu.se.
  • Yuan Zhang
    Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China.
  • Georgios K Vasileiadis
    Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
  • Araz Rawshani
    University of Gothenburg, Institute of Medicine, Sahlgrenska Academy, Gröna Stråket 4, 43146, Gothenburg, Sweden.
  • Ronald van Vollenhoven
    Department of Medicine, Rheumatology Unit, Center for Molecular Medicine (CMM), Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden.
  • Jon Lampa
    Rheumatology Unit, Department of Medicine, Center of Molecular Medicine (CMM), Karolinska Institute, Stockholm, Sweden.
  • Bjorn Gudbjornsson
    Centre for Rheumatology Research, Landspitali University Hospital, Reykjavik, Iceland.
  • Espen A Haavardsholm
    Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway.
  • Dan Nordström
    Division of Medicine and Rheumatology, Helsinki University Hospital, Helsinki, Finland.
  • Gerdur Gröndal
    Centre for Rheumatology Research, Landspitali University Hospital, Reykjavik, Iceland.
  • Kim Hørslev-Petersen
    Danish Hospital for Rheumatic Diseases, University Hospital of Southern Denmark, Sønderborg, Denmark.
  • Kristina Lend
    Department of Medicine, Rheumatology Unit, Center for Molecular Medicine (CMM), Karolinska Institute, Karolinska University Hospital, Stockholm, Sweden.
  • Marte S Heiberg
    Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway.
  • Merete Lund Hetland
    Copenhagen Center for Arthritis Research (COPECARE), Center for Rheumatology and Spine Diseases, Centre of Head and Orthopaedics, Copenhagen University Hospital Rigshospitalet, Glostrup, Denmark.
  • Michael Nurmohamed
    Amsterdam Rheumatology and Immunology Center, Amsterdam University Medical Centers, Amsterdam, Netherlands.
  • Mikkel Østergaard
    Copenhagen Center for Arthritis Research, Center for Rheumatology and Spine Diseases, Rigshospitalet, Copenhagen, Denmark; Department of Clinical Medicine, University of Copenhagen, Copenhagen, Denmark.
  • Till Uhlig
    Center for treatment of Rheumatic and Musculoskeletal Diseases (REMEDY), Diakonhjemmet Hospital, Oslo, Norway.
  • Tuulikki Sokka-Isler
    Department of Medicine, University of Eastern Finland, Jyväskylä Central Hospital, Jyväskylä, Finland.
  • Anna Rudin
    Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.
  • Cristina Maglio
    Department of Rheumatology and Inflammation Research, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden. cristina.maglio@gu.se.